Interestingly, using a donor lymphocyte infusion model for graft-versus-leukemia response (GVL), a combination of CD45-ADC and JAK1/2 inhibition provided a balance between tumor control and GVHD outcome as compared to either treatment alone. Here, PTPRC is linked to leukemia.